Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 25;62(6):e02462-17.
doi: 10.1128/AAC.02462-17. Print 2018 Jun.

Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients

Charalampos Antachopoulos  1 , Stavroula Ilia  2 , Paschalis Kadiltzoglou  1 , Eirini Baira  3 , Aristides Dokoumetzidis  3 , Evangelos Gikas  3 , Eleni Volakli  4 , Maria Sdougka  4 , George Briassoulis  2 , Emmanuel Roilides  5
Affiliations

Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients

Charalampos Antachopoulos et al. Antimicrob Agents Chemother. .

Abstract

The pharmacokinetics of daptomycin (10 mg/kg once daily) was studied in 4 critically ill pediatric patients aged 8 to 14 yrs. The area under the concentration-time curve from time zero to infinity (AUC0-∞) of plasma concentrations on day 1 ranged between 123.8 to 663.9 μg · h/ml, with lower values observed in septic and burn patients; clearance ranged from 15.1 to 80.7 ml/h/kg. Higher-than-recommended doses of daptomycin may be needed in septic children to ensure optimal drug exposure. Interpatient variability may suggest a role for therapeutic drug monitoring.

Keywords: burn; children; critically ill; daptomycin; pharmacokinetics; sepsis.

PubMed Disclaimer

References

    1. Gonzalez-Ruiz A, Seaton RA, Hamed K. 2016. Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. Infect Drug Resist 9:47–58. doi:10.2147/IDR.S99046. - DOI - PMC - PubMed
    1. Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL. 2008. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27:330–334. doi:10.1097/INF.0b013e318160edfc. - DOI - PubMed
    1. Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J, Benziger DP. 2011. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 30:712–714. doi:10.1097/INF.0b013e31820f6575. - DOI - PubMed
    1. Bradley JS, Benziger D, Bokesch P, Jacobs R. 2014. Single-dose pharmacokinetics of daptomycin in pediatric patients 3–24 months of age. Pediatr Infect Dis J 33:936–939. doi:10.1097/INF.0000000000000318. - DOI - PubMed
    1. Bradley J, Glasser C, Patino H, Arnold SR, Arrieta A, Congeni B, Daum RS, Kojaoghlanian T, Yoon M, Anastasiou D, Wolf DJ, Bokesch P. 2017. Daptomycin for complicated skin infections: a randomized trial. Pediatrics 139:e20162477. doi:10.1542/peds.2016-2477. - DOI - PubMed

Publication types

LinkOut - more resources